BridgeMD
Tests treatment safety and results for Lung Cancer
Official title A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
ClinicalTrials.gov ID: NCT06618287
What this study is testing
What is BMS-986507?
BMS-986507 is an investigational medicine, being studied as a potential treatment for lung cancer.
Also referred to as Iza-bren, Izalontamab brengitecan.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
- Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon...
- Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.
You likely can't join if
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants with known mutations in EGFR will be excluded (Group A,B and E).
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
See the full eligibility criteria
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
- Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which...
- Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.
- Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.
- Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen.
- Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants with known mutations in EGFR will be excluded (Group A,B and E).
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Miami, Florida, United States
- Maywood, Illinois, United States
- Iowa City, Iowa, United States
- Hackensack, New Jersey, United States
- Cleveland, Ohio, United States
- Columbus, Ohio, United States
- Portland, Oregon, United States
- Pittsburgh, Pennsylvania, United States
- Knoxville, Tennessee, United States
- Irving, Texas, United States
- Seattle, Washington, United States
- Liverpool, New South Wales, Australia
- Woolloongabba, Queensland, Australia
- East Melbourne, Victoria, Australia
- Subiaco, Western Australia, Australia
- Edmonton, Alberta, Canada
- Newmarket, Ontario, Canada
- Ottawa, Ontario, Canada
- Montreal, Quebec, Canada
+ 35 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Miami, Florida, United States; Maywood, Illinois, United States; Iowa City, Iowa, United States; Hackensack, New Jersey, United States; Cleveland, Ohio, United States and 49 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.